FDA "Critical Path" Faces Roadblock
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency plans to release its list of top priorities several months behind schedule while it focuses on drug safety issues, Acting Deputy Commissioner Woodcock says. Limited FDA resources may jeopardize the project as well.